UK markets close in 1 hour 19 minutes

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.6240-0.0416 (-6.25%)
As of 06:59PM BST. Market open.
Full screen
Previous close0.6656
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Volume50,568
Avg. volumeN/A
Market cap71,018
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-1.6250
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, March 2, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). In parallel to the MAA submission to the UK MHRA, Santhera is currently preparing an application to include vamorolone for the treatment of DMD in the Early Access to Medicines Scheme (EAMS) in the UK. The ai

  • Globe Newswire

    Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Funding intended to support Company through FDA decision on vamorolone in DMDCompany forms Strategy Committee of Board and ManagementIncrease of share capital for private placement and future financings Pratteln, Switzerland, February 28, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces a share placement and an amendme

  • Globe Newswire

    Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, February 8, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the French authorities related to Raxone® (idebenone) for the treatment of Leber's hereditary optic neuropathy (LHON) and sales are expected to resume shortly. In addition, the Company plans to submit a request in France in the near-term for an early access program for vamorolone for the treatment of Duchenne